Summit Therapeutics is holding company. Through its subsidiaries, Co. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicinal therapies. Co.'s ivonescimab is a bispecific antibody that combines the benefits of immunotherapy via a blockade of PD-1 with the anti-angiogenesis benefits of an anti-vascular endothelial growth factor into a single molecule. Co. also focuses on ridinilazole, its product candidate for treating patients suffering from Clostridioides difficile infection. Co.'s other product candidate, SMT-738, is in development for combating multidrug resistant infections, specifically carbapenem-resistant Enterobacteriaceae infections. We show 11 historical shares outstanding datapoints in our coverage of SMMT's shares outstanding history.
Understanding the changing numbers of SMMT shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like SMMT versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching SMMT by allowing them to research SMMT shares outstanding history
as well as any other stock in our coverage universe. |
Free SMMT Email Alerts:
Video: Shares Outstanding Importance
